找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Sample Size Determination in Clinical Trials with Multiple Endpoints; Takashi Sozu,Tomoyuki Sugimoto,Scott R. Evans Book 2015 The Author(s

[復(fù)制鏈接]
樓主: NERVE
11#
發(fā)表于 2025-3-23 10:24:47 | 只看該作者
12#
發(fā)表于 2025-3-23 17:23:13 | 只看該作者
13#
發(fā)表于 2025-3-23 19:16:13 | 只看該作者
14#
發(fā)表于 2025-3-23 22:32:25 | 只看該作者
Convenient Sample Size Formula,ple size formula with associated numerical tables for sizing clinical trials with multiple co-primary endpoints. We provide numerical examples to illustrate use of the formula and associated tables, and provide the programming codes for the R and SAS software packages.
15#
發(fā)表于 2025-3-24 03:46:42 | 只看該作者
Further Developments,elopments for designing randomized trials with other design characteristics including: (i) other inferential goals, (ii) more than two intervention groups, (iii) group sequential designs, and (iv) endpoints with other measurement scales such as time to-event.
16#
發(fā)表于 2025-3-24 09:04:45 | 只看該作者
Binary Co-primary Endpoints,l method with and without a continuity correction, the arcsine method with and without a continuity correction, and the Fisher’s exact method. We evaluate the behavior of the sample size and empirical power associated with the methods. We also provide numerical examples to illustrate the methods.
17#
發(fā)表于 2025-3-24 10:59:56 | 只看該作者
18#
發(fā)表于 2025-3-24 15:50:04 | 只看該作者
Book 2015 multiple primary or co-primary, offering an important reference work for statisticians working in this area..The determination of sample size and the evaluation of power are fundamental and critical elements in the design of clinical trials. If the sample size is too small, important effects may go
19#
發(fā)表于 2025-3-24 19:53:21 | 只看該作者
Introduction,apture a more complete characterization of the intervention effects and provide more informative intervention comparisons. For these reasons, use of more than one primary endpoint has become a common design feature in clinical trials for disease areas such as oncology, infectious disease, and cardio
20#
發(fā)表于 2025-3-25 01:21:07 | 只看該作者
Continuous Co-primary Endpoints,interventions with multiple co-primary continuous endpoints in a clinical trial. We provide numerical examples to illustrate the methods and introduce conservative sample sizing strategies for these clinical trials.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-2-1 02:51
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
蛟河市| 本溪市| 兰西县| 新津县| 大丰市| 闽侯县| 平乐县| 红河县| 林芝县| 昭觉县| 那曲县| 远安县| 太仆寺旗| 翁牛特旗| 临夏县| 淳化县| 澄迈县| 石狮市| 文化| 平原县| 西藏| 浦江县| 酒泉市| 杨浦区| 邛崃市| 陈巴尔虎旗| 咸宁市| 汾西县| 庆云县| 山阳县| 灵丘县| 肥城市| 华亭县| 凉城县| 进贤县| 日照市| 新津县| 紫金县| 察隅县| 于田县| 财经|